Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Rhea-AI Summary
Scilex (Nasdaq:SCLX) plans to list its Dream Bowl I Meme Coin tokens on Biconomy Exchange as early as June 23, 2026. The company believes this may provide liquidity and broad distribution for Participating Holders.
Eligible holders receive 5 Dream Bowl Tokens per SCLX share, based on a record date of April 30, 2026, with distributions beginning May 26, 2026. Biconomy reports over 10 million users, average daily volume of about $2.0 billion, and holds 98% of assets in cold storage.
Positive
- Dream Bowl Tokens to list on Biconomy as early as June 23, 2026
- Eligible holders receive 5 Dream Bowl Tokens for each SCLX share
- Record date set as April 30, 2026 for Participating Holders
- Distribution payment date for tokens began on May 26, 2026
- Biconomy averages about $2.0 billion in daily trading volume
- Biconomy holds approximately 98% of assets in cold storage
Negative
- None.
News Market Reaction – SCLX
In the Jun 16 session, SCLX declined 26.04%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.9% during that session. Argus tracked a trough of -16.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | AI acquisition deal | Positive | +2.0% | Datavault AI and Wellgistics formed DelivMeds AI via multiple asset transactions. |
| May 5 | ACEA Pharma sale | Positive | -3.8% | Definitive agreement to sell ACEA Pharma for Phoenix Asia shares worth $1B. |
| May 4 | Token dividend payment | Positive | +5.4% | Board approved May 26, 2026 payment date for Dream Bowl token dividend. |
| Apr 27 | AI funding deal | Positive | +2.8% | Binding term sheet for $120M Scilex cash contribution to Datavault AI GPU network. |
| Apr 20 | Token dividend approval | Positive | +0.7% | Board approved Dream Bowl token dividend with April 30, 2026 record date. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been received positively: 4 of the last 5 items, mostly strategic deals and token dividends, coincided with share price gains, while a large ACEA Pharma sale announcement saw a negative reaction.
Over the past few months, Scilex highlighted several corporate actions, including a $1,000,000,000 ACEA Pharma sale agreement (May 5, 2026) and multiple Dream Bowl token dividend announcements with distributions of about 81.4 million tokens and 5 tokens per share. These token-related updates on April 20 and May 4, 2026 were followed by modest price gains of 0.65% and 5.39%. Today’s news on token listing extends that storyline by focusing on secondary market liquidity for the issued tokens.
Key Terms
meme coin financial
digital wallets technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced Dream Bowl I Meme Coin tokens (“Dream Bowl Tokens”) to list on Biconomy Exchange as early as June 23, 2026.
Scilex believes that such listing may deliver liquidity and allow for broad distribution of such tokens for the Participating Holders (as defined below). Biconomy serves more than 10 million users and institutions across 180+ countries and consistently ranks among the top 40 global exchanges by trading volume, with average daily volume of approximately
As previously announced, stockholders and certain other eligible equityholders of Scilex (collectively, the “Participating Holders”) as of record date of April 30, 2026 became entitled to receive five (5) Dream Bowl Tokens for each share of Scilex common stock held (or for each share of common stock issuable or deemed issuable upon exercise or conversion of such other eligible securities). The payment date for such distribution began on May 26, 2026, subject to the holder’s satisfaction of certain payment conditions previously disclosed by Scilex.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur Pharmaceuticals, Inc. (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur is headquartered in Palo Alto, California
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex’s belief that the potential listing of the Dream Bowl Tokens on Biconomy Exchange may deliver liquidity to the holders thereof and allow broad distribution of such tokens. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
Scilex Bio™ is a trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2026 Scilex Holding Company All Rights Reserved.
